Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Standard
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. / Witzel, Isabell; Loibl, Sibylle; von Minckwitz, Gunter; Mundhenke, Christoph; Huober, Jens; Hanusch, Claus; Henschen, Stephan; Hauschild, Maik; Lantzsch, Tilmann; Tesch, Hans; Latos, Kunibert; Just, Marianne; Hilfrich, Jörn; Barinoff, Jana; Zu Eulenburg, Christine Gräfin; Roller, Marc; Untch, Michael; Müller, Volkmar.
in: BREAST CANCER RES TR, Jahrgang 123, Nr. 2, 2, 2010, S. 437-445.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
AU - Witzel, Isabell
AU - Loibl, Sibylle
AU - von Minckwitz, Gunter
AU - Mundhenke, Christoph
AU - Huober, Jens
AU - Hanusch, Claus
AU - Henschen, Stephan
AU - Hauschild, Maik
AU - Lantzsch, Tilmann
AU - Tesch, Hans
AU - Latos, Kunibert
AU - Just, Marianne
AU - Hilfrich, Jörn
AU - Barinoff, Jana
AU - Zu Eulenburg, Christine Gräfin
AU - Roller, Marc
AU - Untch, Michael
AU - Müller, Volkmar
PY - 2010
Y1 - 2010
N2 - In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial. This study incorporated NT approaches and additional trastuzumab treatment for all patients with HER2-positive tumors. Human epidermal growth factor receptor 2 serum levels were measured by enzyme-linked immunosorbent assay (ELISA) before initiation of NT and after NT (pre-surgery) in a HER2-positive (n = 90) and a HER2-negative patient cohort (n = 85). Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status of the primary tumor than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P <0.001). A pre-chemotherapy sHER2 cut-off level of 10 ng/ml had the best sensitivity and specificity in discriminating between HER2-positive and HER2-negative primary tumors. In HER2-positive patients, we found a significant positive association between pathological complete remission (pCR) and elevated sHER2 levels (above 15 ng/ml, P = 0.045) and a decrease of sHER2 levels during NT (P = 0.02), which was also significant in multivariate analysis (OR = 3.29, 95% CI 1.001-10.89, P = 0.049). In HER2-negative patients, we observed no association between sHER2 levels and pCR (P > 0.05). Monitoring sHER2 levels in the presence of anti-HER2 treatment might be an adjunct to the clinical evaluation during NT.
AB - In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial. This study incorporated NT approaches and additional trastuzumab treatment for all patients with HER2-positive tumors. Human epidermal growth factor receptor 2 serum levels were measured by enzyme-linked immunosorbent assay (ELISA) before initiation of NT and after NT (pre-surgery) in a HER2-positive (n = 90) and a HER2-negative patient cohort (n = 85). Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status of the primary tumor than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P <0.001). A pre-chemotherapy sHER2 cut-off level of 10 ng/ml had the best sensitivity and specificity in discriminating between HER2-positive and HER2-negative primary tumors. In HER2-positive patients, we found a significant positive association between pathological complete remission (pCR) and elevated sHER2 levels (above 15 ng/ml, P = 0.045) and a decrease of sHER2 levels during NT (P = 0.02), which was also significant in multivariate analysis (OR = 3.29, 95% CI 1.001-10.89, P = 0.049). In HER2-negative patients, we observed no association between sHER2 levels and pCR (P > 0.05). Monitoring sHER2 levels in the presence of anti-HER2 treatment might be an adjunct to the clinical evaluation during NT.
M3 - SCORING: Zeitschriftenaufsatz
VL - 123
SP - 437
EP - 445
JO - BREAST CANCER RES TR
JF - BREAST CANCER RES TR
SN - 0167-6806
IS - 2
M1 - 2
ER -